Newron Pharma key value driver is Xadago, says ValuationLAB

23 June 2016

Italian CNS-focused drug developer Newron Pharmaceuticals’ (SIX: NWRN) key value driver is safinamide (branded Xadago), a once daily oral add-on therapy for all stages of Parkinson's disease with a unique dual mechanism of action, according to a new report on the company from ValuationLAB.

Xadago was first launched in the European Union in the second quarter of 2015.

On March 29, the drug unexpectedly received a US Food and Drug Administration Complete Response Letter (CRL), pushing back US approval by an estimated 12-18 months. Xadago was licensed to Meiji Seika (Japan & Asian markets) and Zambon (worldwide excluding Meiji Seika territories) in 2012. Substantial revenues are expected from sub-licensing, milestone and royalty payments from Xadago sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK